DDW - Digestive Disease Week 2016

Conference Reports for NATAP


DDW - Digestive Disease Week 2016 May 16-19, 2016 San Diego, CA

	Cost per Sustained Virological Response 4 (SVR 4) in Genotype 1 Patients Treated With Sofosbuvir and Ledipasvir With and Without Ribavirin. A Detailed Cost-Mapping Study - (06/27/16) Integrated Analysis Of Studies Evaluating The Treatment of Chronic Hepatitis C Genotype 4 With Interferon-Free Sofosbuvir-Based Regimens - (06/08/16) High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies - (06/08/16) The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis - (06/08/16) Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients - (06/06/16) Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates in Patients With Negative Predictors of Response to Treatment: an Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (06/06/16) Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness - (06/06/16) Real World Effectiveness of Ledipasvir/Sofosbuvir in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic HCV: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts - (06/06/16) Failure with All-oral DAA Regimens: Real-World Experience from the Trio Network - (05/27/16) HIGH SVR RATES WITH THE COMBINATION OF ABT-493 + ABT-530 FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 OR 2 INFECTION - (05/26/16) SURVEYOR-I: 100% SVR12 AND FAVORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED FOR 12 WEEKS IN NON-CIRRHOTIC PATIENTS WITH GENOTYPES 4, 5, OR 6 INFECTION - (05/26/16) DDW/2016: Access to Therapy in Era of All DAA Regimens: Real World Experience from the TRIO Network - (05/26/16) DDW/2016: Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-infected with HCV and HIV: Real-world Heterogeneous Population from the TRIO Network - Academic and community treatment of a real-world, heterogeneous population - (05/26/16) DDW/2016: A New Digital Health Feedback Offering to Keep Patients Adherent to Oral Hepatitis C Therapy - (05/26/16) DDW/2016: Barriers to [Veterans] Hepatitis C Treatment in the DAA era - (05/26/16) QUARTZ-I: OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY - (05/26/16) DDW/2016: Factors Affecting Approval Rates of Direct Acting Antivirals (DAA) for Hepatitis C Infection: A Single Center Experience - (05/25/16)